ZNTL Earnings & Financial Statements
Zentalis Pharmaceuticals, Inc.
$2.24
-$0.08(-3.47%)
34
Overall
60
Value
18
Tech
26
Quality
Market Cap
$227.20M
Volume
544.04K
52W Range
$1.21 - $6.95
Target Price
$7.70
ZNTL earnings and financial statements: Zentalis Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ZNTL Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $67.42M | $900.0K | - | - |
| Operating income | -$152.81M | -$191.19M | -$299.51M | -$227.29M | -$216.54M |
| EBITDA | -$135.92M | -$164.39M | -$291.51M | -$236.18M | -$216.00M |
| Net income | -$137.06M | -$165.84M | -$292.19M | -$236.81M | -$158.72M |
| EPS (diluted) | $-1.91 | $-2.33 | $-4.47 | $-4.48 | $-3.72 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $288.97M | $430.34M | $551.69M | $539.31M | $454.51M |
| Total liabilities | $72.76M | $93.15M | $114.30M | $105.29M | $90.03M |
| Shareholders’ equity | $216.20M | $337.19M | $437.28M | $433.80M | $363.95M |
| Cash and equivalents | $35.99M | $33.90M | $28.04M | $43.07M | $59.71M |
| Long-term debt | $35.70M | $39.58M | $43.15M | $45.17M | $44.46M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$125.25M | -$170.86M | -$207.82M | -$163.75M | -$154.09M |
| Capital expenditure | $698.0K | -$156.0K | -$583.0K | -$2.55M | -$6.11M |
| Free cash flow | -$125.25M | -$171.08M | -$208.41M | -$166.30M | -$160.20M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ZNTL | $2.24 | -3.5% | 544.04K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Zentalis Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW